Akebia Therapeutics, Inc. (AKBA) News

Akebia Therapeutics, Inc. (AKBA): $1.06

0.06 (+6.00%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add AKBA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#55 of 342

in industry

Filter AKBA News Items

AKBA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AKBA News Highlights

  • For AKBA, its 30 day story count is now at 9.
  • Over the past 26 days, the trend for AKBA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DRUG, LOAN and BEAT are the most mentioned tickers in articles about AKBA.

Latest AKBA News From Around the Web

Below are the latest news stories about AKEBIA THERAPEUTICS INC that investors may wish to consider to help them evaluate AKBA as an investment opportunity.

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST.

Yahoo | November 20, 2023

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript November 8, 2023 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.09. Operator: Good day and thank you for standing by. Welcome to the Akebia Therapeutics’ Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only […]

Yahoo | November 9, 2023

Q3 2023 Akebia Therapeutics Inc Earnings Call

Q3 2023 Akebia Therapeutics Inc Earnings Call

Yahoo | November 9, 2023

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

Yahoo | November 8, 2023

Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has amended the terms of its loan agreement with Pharmakon Advisors, LP, the investment manager of the BioPharma Credit funds that it originally entered into in November 2019. The amendment extends the maturity date of the loan to March of 2025 from November 11, 2024. Under the terms of the amendment, Akebia's quarterly principal pay

Yahoo | November 2, 2023

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 61,000 shares of Akebia's common stock on October 31, 2023, as an inducement material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | November 1, 2023

Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023, prior to the open of financial markets.

Yahoo | October 31, 2023

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 26, 2023

Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the U.S. Food and Drug Administration (FDA) has acknowledged that the resubmission to its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis, was complete. The FDA has classified this as a class 2 response, which results in a six-month review period from

Yahoo | October 25, 2023

Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023.

Yahoo | October 18, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!